Royal DSM Raised to Buy From Hold by Jefferies
Royal DSM Raised to Buy From Hold by Jefferies
Royal DSM Announced Sale on April 20
Royal DSM Announced Sale on April 20
DSM Has Sold Business to Avient Corp for Enterprise Value of EUR1.45B
DSM Has Sold Business to Avient Corp for Enterprise Value of EUR1.45B
Royal DSM Completes Sale of Protective Materials Business
Royal DSM Completes Sale of Protective Materials Business
Koninklijke DSM N.V. Non-GAAP EPS of €1.89, revenue of €4.11B misses by €1.11B
Koninklijke DSM N.V. press release (OTCQX:RDSMY): 1H Non-GAAP EPS of €1.89. Revenue of €4.11B (+17.1% Y/Y) misses by $1.11B.
Royal DSM 2Q Adj. Ebitda Rose Ahead of Market Views; Outlook for 2022 Unchanged
By Sabela Ojea Royal DSM NV reported on Tuesday a rise in adjusted Ebitda from continuing operations for the second quarter of 2022, beating market views, and said that it continues to expect further
Royal DSM to Deliver High-Single Digit Adjusted Ebitda Increase for 2022
Royal DSM to Deliver High-Single Digit Adjusted Ebitda Increase for 2022
Royal DSM Sales of Health, Nutrition, Bioscience Division Up 19%
Royal DSM Sales of Health, Nutrition, Bioscience Division Up 19%
Royal DSM 2Q Adj. Ebitda Margin 18%
Royal DSM 2Q Adj. Ebitda Margin 18%
Royal DSM: Conditions Improved in 2Q
Royal DSM: Conditions Improved in 2Q
Royal DSM: Strong Volume, Price Momentum in June Going into 3Q
Royal DSM: Strong Volume, Price Momentum in June Going into 3Q
Royal DSM 2Q Sales Were Seen to Be EUR1.79B
Royal DSM 2Q Sales Were Seen to Be EUR1.79B
Royal DSM NV 2Q Sales EUR2.11B
Royal DSM NV 2Q Sales EUR2.11B
Royal DSM NV 2Q Adj. Ebitda from Continuing Operations EUR379M
Royal DSM NV 2Q Adj. Ebitda from Continuing Operations EUR379M
Royal DSM NV's 2Q Adj. Ebitda Was Seen to Be EUR360M
Royal DSM NV's 2Q Adj. Ebitda Was Seen to Be EUR360M
Royal DSM NV Sees FY Trading in Line With Views
Royal DSM NV Sees FY Trading in Line With Views
Royal DSM Confirms Rise in 1Q Sales, Adjusted Earnings After Restatement
By Joe Hoppe Royal DSM NV on Tuesday reaffirmed that sales and adjusted earnings rose in the first three months of 2022, after restating figures to reflect the sale of its material businesses. The D
Dwindling Russian Gas Supplies Could Squeeze European Chemical Margins -- Market Insight
Commentary by Adrià Calatayud Higher natural-gas prices and reduced supplies from Russia could hurt European chemical companies' profit margins in the short term, as they could coincide with a slowdo
Royal DSM: Acquisition Expected to Close This Year
Royal DSM: Acquisition Expected to Close This Year
Royal DSM: Prodap is a Brazilian Animal Nutrition, Technology Company
Royal DSM: Prodap is a Brazilian Animal Nutrition, Technology Company
No Data